ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年07月31日 14時41分
Source:
Eisai
エーザイ、2020年3月期配当予想の修正(増配)に関するお知らせ
東京, 2019年07月31日 - (JCN Newswire) - 当社は、2019年7月31日開催の取締役会において、2020年3月期第2四半期末(中間)配当の予想について、下記の通り、修正(増配)することを決議しましたので、お知らせします。
1. 配当予想の修正について
2020年3月期第2四半期末(中間)配当の予想の修正(増配)
年間配当金(円)
第2四半期末/期末/合計
前回予想(2019年5月13日公表)70円00銭/80円00銭/150円00銭
今回修正予想 80円00銭/80円00銭/160円00銭
当期実績 -/-/-
前期実績(2019年3月期)70円00銭/80円00銭/150円00銭
2. 修正の内容
当社は、主要なステークホルダーズである患者様と生活者の皆様、株主の皆様および社員の価値増大をはかるとともに良好な関係の発展・維持に努めています。
配当につきましては、長期的なバランスシートマネジメントに依拠した「最適資本構成に基づく最適配当政策」を志向しており、連結業績、DOE(親会社所有者帰属持分配当率)およびフリー・キャッシュ・フローを総合的に勘案し、「シグナリング効果」も考慮して、株主の皆様へ継続的・安定的な配当を実施します。配当のKPIとしては、連結純資産に対する配当の比率を示すDOEを採択しています。
今回、これらの配当方針、ならびに好調な業績に基づく強固なバランスシートを勘案し、前回発表(2019年5月13日)の2020年3月期第2四半期末(中間)配当金予想を10円増配の80円に修正します。2010年3月期以来となる増配により期末配当金予想80円と合わせ、年間配当金予想は160円(前回予想は150円)、2020年3月期通期業績予想に基づくDOEは7.1%となる見込みです。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201959.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 04, 2025 15:56 JST
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 04, 2025 09:04 JST
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 03, 2025 22:10 JST
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 03, 2025 07:00 JST
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 02, 2025 17:41 JST
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Apr 01, 2025 12:25 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
More Latest Release >>
Related Release
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
More Press release >>